American Society of Clinical Oncology

SHERPA: White

People

  1. Slovin
    Slovin
  2. Scher
    Scher
  3. Morris
    Morris
  4. De La Cruz
    De La Cruz
  5. Fleisher
    Fleisher
  6. Autio
    Autio
  7. Danila
    Danila
  8. Rathkopf
    Rathkopf
  9. Heller
    Heller
  10. Chen
    Chen

Groups

  1. Department of Medicine (21)
  2. Genitourinary Oncology Service (21)
  3. Hematologic Malignancies, Division of (21)
  4. Nursing (21)
  5. Solid Tumor Oncology Division (21)
  6. GSK Faculty (11)
  7. Advanced Practice Providers (8)
  8. Molecular Imaging and Therapy Service (7)
  9. Molecular Pharmacology and Chemistry Program Faculty (7)
  10. Radiology, Department of (7)
Search Within
  1. "Susan Slovin"
  2. "Nursing"
Formats
  1. Meeting Abstract (16)
  2. Journal Article (5)
Groups
  1. Department of Medicine (21)
  2. Genitourinary Oncology Service (21)
  3. Hematologic Malignancies, Division of (21)
  4. Nursing (21)
  5. Solid Tumor Oncology Division (21)
  6. GSK Faculty (11)

More Groups

People
  1. Susan Slovin (21)
  2. Howard Scher (19)
  3. Tracy Smart-Curley (14)
  4. Michael Morris (13)
  5. Anthony De La Cruz (8)
  6. Gabrielle Arauz (8)

More People

Years
  1. 2023 (1)
  2. 2020 (1)
  3. 2017 (1)
  4. 2016 (2)
  5. 2013 (2)
  6. 2012 (2)

More Years

Publications
  1. Journal of Clinical Oncology (21)

Results (21)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Randomized phase II multicenter trial of abiraterone acetate with or without cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
    Journal Article

    Slovin, S. F.; Knudsen, K.; Halabi, S.; de Leeuw, R.; Shafi, A.; Kang, P.; Wolf, S.; Luo, B.; Gopalan, A.; Curley, T.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Evaluation of immune-related adverse events (irAE): Utilizing the patient-reported outcomes of the common terminology criteria for adverse events (PRO-CTCAE) in a phase II study of ipilimumab (ipi) in men with castration-sensitive prostate cancer (CSPC)
    Meeting Abstract

    Vargas Pivato de Almeida, D.; Anderson, J.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Abida, W.; Dayan, E. S.; Curley, T.; Arauz, G.; Baser, R. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Halabi, S.; Carbone, E.; Fernandez, C.; Chen, Y.; Autio, K. A.; Rathkopf, D. E.; Kampel, L.; Morris, M. J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Exploring the role of RB and AR in a phase II randomized multicenter trial of abiraterone acetate with or without cabazitaxel in metastatic castration resistant prostate cancer (mCRPC)
    Meeting Abstract

    Slovin, S. F.; Knudsen, K. E.; Carbone, E.; Showunmi, A.; Hullings, M.; Morris, M. J.; Autio, K. A.; Kampel, L. J.; Molina, A. M.; Chen, Y.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • A Phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Slovin, S. F.; Autio, K. A.; Delacruz, A.; Shelkey, G.; Pisano, K.; Hullings, M.; DeNunzio, M.; Morris, M. J.; Scher, H. I.
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Sadelain, M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Chimeric antigen receptor (CAR(+)) modified T cells targeting prostate specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC)
    Meeting Abstract

    Slovin, S. F.; Wang, X.; Hullings, M.; Arauz, G.; Bartido, S.; Lewis, J. S.; Schoder, H.; Zanzonico, P.; Scher, H. I.; Riviere, I.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase I study of the androgen signaling inhibitor ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Curley, T.; Rix, P. J.; Maneval, E. C.; Chen, I.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Meeting Abstract

    Rathkopf, D. E.; Danila, D. C.; Morris, M. J.; Slovin, S. F.; Steinbrecher, J. E.; Arauz, G.; Rix, P. J.; Maneval, E. C.; Chen, I.; Fox, J. J.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • A phase I dose-escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in patients (pts) with castration-resistant prostate cancer (CRPC): Final results
    Meeting Abstract

    Slovin, S. F.; Morris, S.; Kargman, M.; Durso, R.; Curley, T.; Israel, R. J.; Olson, W. C.; Murphy, D.; Scher, H. I.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save